This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Tanigaki, N. Articles by Pressman, D. Search for Related Content PubMed PubMed Citation Articles by Tanigaki, N. Articles by Pressman, D.

The Reaction of Specific Antibody with 2-Acetylaminofluorene Fixed in Liver Cells¹

Department of Biochemistry Research, Roswell Park Memorial Institute,⁴ Buffalo, New York 14203

Rabbit antibody specific to the 2-azofluorenyl group (anti-2-AzF antibody) was used to investigate the behavior of cellular components capable of binding 2-acetylaminofluorene (2-AAF) in rat livers during the chemical carcinogenesis.

The fixation of the anti-2-AzF antibody in vitro by liver sections of rats fed or injected with fluorenyl derivatives was quantitatively measured by the radioiodine-labeled antibody technic. The anti-2-AzF antibody was fixed to a higher extent at earlier stages of 2-AAF feeding than at later stages. No definite fixation of the antibody was observed 2 weeks after completing the feeding schedule of 16 weeks. When rats on normal diet after completing the 2-AAF feeding were injected with 2-AAF and assayed, the antibody reacted more weakly with hepatomatous nodules than with preneoplastic or normal liver, indicating the presence of carcinogen-binding components at the preneoplastic stage. The concentration of these components in hepatomatous nodules was much lower.

Cellular distribution of the carcinogen in the livers of these rats was determined by fluorescent antibody technic. The results clearly demonstrated that carcinogen-binding components of hepatic cells are present at a particularly high concentration in the cell boundary and the perinuclear zone and that these components are partially deleted in cells of hyperplastic nodules which appear at the later stage of the 2-AAF feeding, and almost completely deleted in hepatomatous cells.

¹ Supported in part by Contract #AT(30-1)2651 from the U.S. Atomic Energy Commission and Grant 242-C from the American Cancer Society.

² On leave from the Institute for Cancer Immunopathology, Hokkaido University, Sapporo, Japan.

³ On leave from the Institute for Cancer Research, School of Medicine, Osaka University, Osaka, Japan.

⁴ A unit of the New York State Department of Health.

Received 8/15/66. Accepted 12/ 2/66.